OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Rau on Treatment With Blinatumomab and Chemo in Newly Diagnosed Pediatric B-ALL

December 10th 2024

Rachel E. Rau, MD, discusses findings that show blinatumomab plus chemotherapy improves DFS in newly diagnosed B-ALL.

Dr Iams on the Importance of Anti-VGCC Antibody Testing for LEMS in SCLC

December 10th 2024

Wade T. Iams, MD, discusses the importance of performing anti-VGCC antibody testing for suspected Lambert-Eaton Myasthenic Syndrome in SCLC.

Dr Kuykendall on the Advantages of Treatment With Momelotinib in Myelofibrosis

December 10th 2024

Andrew Kuykendall, MD, discusses the advantages of treatment with momelotinib vs older-generation JAK inhibitors in myelofibrosis.

Dr Fenske on ASCT Outcomes in MCL After First MRD-Negative CR

December 10th 2024

Timothy S. Fenske, MD, MS, shares outcomes from the phase 3 ECOG-ACRIN EA4151 trial of patients with mantle cell lymphoma after first MRD-negative CR.

Dr Lee on Real-World Early Outcomes With Second-Line Axi-Cel for R/R LBCL

December 10th 2024

Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.

Dr Poh on the Preliminary Efficacy of Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma

December 10th 2024

Christina Poh, MD, discusses results from the phase 3 inMIND study of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Dr Matasar on the Use of Odronextamab Monotherapy in R/R DLBCL Following CAR T-Cell Therapy

December 10th 2024

Matthew Matasar, MD, discusses treatment with odronextamab monotherapy in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.

Dr Landgren on the Utility of Tocilizumab Prophylaxis in Relapsed/Refractory Multiple Myeloma

December 10th 2024

C. Ola Landgren, MD, PhD, discusses tocilizumab prophylaxis in relapsed/refractory myeloma treated with teclistamab, elranatamab, or talquetamab.

Dr Sekeres on Luspatercept Plus Lenalidomide in Non–5q Deletion MDS

December 9th 2024

Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.

Dr Rifkin on Efficacy and Safety Data From the Dreamm-7 Trial in R/R Myeloma

December 9th 2024

Robert M. Rifkin, MD, FACP, discusses the safety and efficacy of the phase 3 Dreamm-7 trial in patients with relapsed/refractory multiple myeloma.

Dr Siegel on the Preliminary Use of Mezigdomide in Relapsed/Refractory Myeloma

December 9th 2024

David Samuel Dicapua Siegel, MD, discusses preliminary findings from the phase 1/2 CA057-003 trial of mezigdomide in relapsed/refractory multiple myeloma.

Dr Foster on Daratumumab Plus Lenalidomide in Newly Diagnosed Myeloma After Transplant

December 9th 2024

Laahn Foster, MD, shares data on daratumumab and lenalidomide vs lenalidomide alone as maintenance in newly diagnosed multiple myeloma after transplant.

Dr Mauz-Koerholz on the Role of Pembrolizumab in Younger Patients With Low-Risk Classic Hodgkin Lymphoma

December 8th 2024

Christine Mauz-Koerholz, MD, PhD, discusses updated results from the phase 2 KEYNOTE-667 trial, which were shared at the 2024 ASH Annual Meeting.

Dr Kaddoura on Genomic Determinants of Outcomes in IGH/CCND1+ Myeloma Treated With Venetoclax

December 8th 2024

Marcella Ali Kaddoura, MD, discusses genomic determinants of clinical outcomes in myeloma with t(11;14)(CCND1;IGH) treated with venetoclax.

Dr Zackon on the Use of Bispecific Antibodies in the Community Setting for R/R Myeloma

December 8th 2024

Ira Zackon, MD, discusses findings on the real-world utilization of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma in the community oncology setting.

Dr Jurczak on the Efficacy and Safety of Nemtabrutinib in R/R Follicular Lymphoma

December 8th 2024

Wojciech Jurczak, MD, PhD, discusses the safety and efficacy of nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma.

Drs Baljevic and Cortes Preview Upcoming Studies and Emerging Data From ASH 2024

December 6th 2024

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

Dr Liu on the TRUST-II Trial of Taletrectinib in ROS1+ NSCLC

December 6th 2024

Stephen V. Liu, MD, discusses updated data from the phase 2 TRUST-II trial investigating taletrectinib in ROS1-positive non–small cell lung cancer.

Dr Stein on the Impact of Revumenib on Survival Outcomes in KMT2A-Rearranged R/R Acute Leukemia

December 6th 2024

Eytan M. Stein, MD, discusses how the FDA approval of revumenib could improve survival outcomes in KMT2A-rearranged relapsed/refractory acute leukemia.

Dr Stearns on the Role of Carboplatin in Early-Stage TNBC

December 6th 2024

Vered Stearns, MD, discusses the role of carboplatin in early-stage triple-negative breast cancer according to results from the phase 3 PEARLY trial.